Local view for "https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/698"
| Predicate | Value (sorted: default) |
|---|
| rdfs:label |
"evidence_1844"
|
| rdf:type |
|
| ?:Evidence_enzyme_system |
|
| ?:Evidence_type |
|
| ?:content |
"CYP3A4 Isozyme�Nefazodone has been shown in vitro to be an inhibitor of CYP3A4. This is consistent with the interactions observed between nefazodone and triazolam, alprazolam, buspirone, atorvastatin, and simvastatin, drugs metabolized by this isozyme. Consequently, caution is indicated in the combined use of nefazodone with any drugs known to be metabolized by CYP3A4. In particular, the combined use of nefazodone with triazolam should be avoided for most patients, including the elderly. The combined use of nefazodone with terfenadine, astemizole, cisapride, or pimozide is contraindicated (see CONTRAINDICATIONS and WARNINGS)."
|
| dc:creator |
|
| dc:date |
|
| rdfs:seeAlso |
|
All properties reside in the graph file:///home/swish/src/ClioPatria/guidelines/dikb.ttl
The resource appears as object in one triple:
{ nefazodone_does_not_inhibit_cyp3a4, <http://purl.org/swan/1.2/swan-commons#citesAsRefutingEvidence>, evidence_1844 }
Context graph
